Ablynx, a Sanofi company

Ablynx, a Sanofi company

Ablynx, a Sanofi company

Ablynx, a Sanofi company, is focused on the discovery and development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.

The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programs.

REGISTER AS A DELEGATE NOW

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners